L773:0161 5505 OR L773:2159 662X
Search: L773:0161 5505 OR L773:2159 662X > (2015-2019) > Recombinant alpha(1...
- 5 of 83
- Previous record
- Next record
- To hitlist
- Andersson, CharlotteUniversity of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för radiofysik,Sahlgrenska Cancer Center,Institute of Clinical Sciences, Department of Radiation Physics (author)
Recombinant alpha(1)-Microglobulin Is a Potential Kidney Protector in Lu-177-Octreotate Treatment of Neuroendocrine Tumors
- Article/chapterEnglish2019
Publisher, publication year, extent ...
- 2019-03-29
- Society of Nuclear Medicine,2019
Numbers
- LIBRIS-ID:oai:gup.ub.gu.se/286382
- https://gup.ub.gu.se/publication/286382URI
- https://doi.org/10.2967/jnumed.118.225243DOI
- https://lup.lub.lu.se/record/f39753d5-77fe-4c51-9aed-23c2859f44b6URI
Supplementary language notes
- Language:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- Treatment of neuroendocrine tumors with Lu-177-octreotate results in prolonged survival and improved quality of life for the patient. However, the treatment is today limited by side effects on kidney and bone marrow, and complete tumor remission is rarely seen. A possible way to minimize dose-limiting toxicity and to optimize this treatment method is to use radioprotectors in conjunction with radiotherapy. A recombinant form of alpha(1)-microglobulin ( rA1M) was recently shown to preserve kidney structure and function after Lu-177-octreotate injection in mice and was suggested as a radioprotector in peptide receptor radionuclide therapy. The aims of this work were to investigate the influence of rA1M on the in vivo biokinetics of Lu-177-octreotate, with a focus on tumor tissue, and to study the impact of rA1M on the therapeutic response in tumor tissue subjected to Lu-177-octreotate treatment. Methods: The biodistribution of Lu-177-octreotate was examined in BALB/c nude mice with GOT2 tumors 1-168 h after injection with either Lu-177-octreotate or coadministration of 177Lu-octreotate and rA1M. The effects of rA1M on the tumor response after Lu-177-octreotate treatment were studied in BALB/c nude mice with GOT1 tumors. Three groups of mice were administered rA1M, Lu-177-octreotate, or both. Another group served as untreated controls. Tumor volume was measured to follow the treatment effects. Results: No statistically significant difference in biodistribution of Lu-177 was observed between the groups receiving Lu-177-octreotate or coinjection of Lu-177-octreotate and rA1M. The therapy study showed a decrease in mean tumor volume during the first 2 wk for both the Lu-177-octreotate group and the coadministration group, followed by tumor regrowth. No statistically significant difference between the groups was found. Conclusion: rA1M did not negatively impact absorbed dose to tumor or therapeutic response in combination with Lu-177-octreotate and may be a promising kidney protector during Lu-177-octreotate treatment of patients with neuroendocrine tumors.
Subject headings and genre
- MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Cancer och onkologi hsv//swe
- MEDICAL AND HEALTH SCIENCES Clinical Medicine Cancer and Oncology hsv//eng
- alpha(1)-microglobulin
- somatostatin receptors
- GOT1
- GOT2
- radioprotector
- medullary-thyroid carcinoma
- radionuclide therapy
- lipocalin
- alpha(1)-microglobulin
- radiolabeled somatostatin
- nude-mice
- biodistribution
- toxicity
- model
Added entries (persons, corporate bodies, meetings, titles ...)
- Shubbar, Emman,1974University of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för radiofysik,Sahlgrenska Cancer Center,Institute of Clinical Sciences, Department of Radiation Physics(Swepub:gu)xshuem (author)
- Schuler, E.Stanford University School of Medicine (author)
- Åkerström, BoLund University,Lunds universitet,Infektionsmedicin,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Antioxidationsmedicin,Forskargrupper vid Lunds universitet,Infection Medicine (BMC),Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Antioxidation medicine,Lund University Research Groups(Swepub:lu)medk-bak (author)
- Gram, MagnusLund University,Lunds universitet,Antioxidationsmedicin,Forskargrupper vid Lunds universitet,Neonatalogi,Sjukdomsorsakande oxidation,Antioxidation medicine,Lund University Research Groups,Neonatology,Redox Medicine,A1M Pharma AB(Swepub:lu)medk-mo0 (author)
- Forssell-Aronsson, Eva,1961University of Gothenburg,Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center,Institutionen för kliniska vetenskaper, Avdelningen för radiofysik,Institute of Clinical Sciences, Department of Radiation Physics(Swepub:gu)xforev (author)
- Göteborgs universitetInstitutionen för kliniska vetenskaper, Avdelningen för radiofysik (creator_code:org_t)
Related titles
- In:Journal of Nuclear Medicine: Society of Nuclear Medicine60:11, s. 1600-16040161-55052159-662X
Internet link
Find in a library
- Journal of Nuclear Medicine (Search for host publication in LIBRIS)
To the university's database
- 5 of 83
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Andersson, Charl ...
- Shubbar, Emman, ...
- Schuler, E.
- Åkerström, Bo
- Gram, Magnus
- Forssell-Aronsso ...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- Journal of Nucle ...
- By the university
- University of Gothenburg
- Lund University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
